Description

Simple

Clinical

Overview

Fimasartan is an angiotensin II receptor antagonist (ARB) drug employed in the treatment of both hypertension and heart failure. It has been found to be safe when administered with hydrochlorothiazide (a diuretic) in clinical trials. Fimasartan was initially approved September 9th, 2010 in South Korea and is marketed under the brand name _Kanarb_ by Boryung Pharmaceuticals.

Pharmacology

Indication

Used for the treatment of hypertension and heart failure [1].

Pharmacodynamic

Fimasartan is a selective angiotensin receptor 1 (AR1) inhibitor [1].... Read more

Mechanism of action

Angiotensin II activates AR1 leading to vasoconstriction and increased noradrenaline release which further increases vasoconstriction via action at α1-adrenergic receptors [ Read more

Absorption

Tmax is 0.5-1.3 h [1].

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

The half life of elimination is 7-10 h [1].

Route of elimination

Most is eliminated unchangd in bile with less than 3% in the urine [1]... Read more

Toxicity

Information currently not available.

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Fimasartan
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the orthostatic hypotensive activities of Fimasartan.
Abemaciclib
Abemaciclib may decrease the excretion rate of Fimasartan which could result in a higher serum level.
Acebutolol
The risk or severity of hyperkalemia can be increased when Acebutolol is combined with Fimasartan.
Aceclofenac
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Aceclofenac.
Acemetacin
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Acemetacin.
Acetylcysteine
The excretion of Fimasartan can be decreased when combined with Acetylcysteine.
Acetylsalicylic acid
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Acetylsalicylic acid.
Afatinib
Afatinib may decrease the excretion rate of Fimasartan which could result in a higher serum level.
Agmatine
The risk or severity of hyperkalemia can be increased when Agmatine is combined with Fimasartan.
Alclofenac
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Alclofenac.
Aldesleukin
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Fimasartan.
Alectinib
Alectinib may decrease the excretion rate of Fimasartan which could result in a higher serum level.
Aliskiren
The risk or severity of hyperkalemia can be increased when Aliskiren is combined with Fimasartan.
Alminoprofen
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Alminoprofen.
Alprenolol
The risk or severity of hyperkalemia can be increased when Alprenolol is combined with Fimasartan.
Ambrisentan
The therapeutic efficacy of Ambrisentan can be increased when used in combination with Fimasartan.
Amifostine
The risk or severity of adverse effects can be increased when Amifostine is combined with Fimasartan.
Amiloride
The risk or severity of hyperkalemia can be increased when Fimasartan is combined with Amiloride.
Aminohippuric acid
The excretion of Fimasartan can be decreased when combined with Aminohippuric acid.
Aminophenazone
The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Aminophenazone.
2 References
  1. 1 . Kim JH, Lee JH, Paik SH, Kim JH, Chi YH: Fimasartan, a novel angiotensin II receptor antagonist. Arch Pharm Res. 2012 Jul;35(7):1123-6. doi: 10.1007/s12272-012-0700-z.PubMed: 22864732
  2. 2 . Rang, H. P. and Dale, M. M. (2012). Rang and Dale's Pharmacology (7th ed.). Edinburgh: Elsevier/Churchill Livingstone.